Quality of life in patients with chronic rhinosinusitis.
Curr Allergy Asthma Rep. 2011; 11: 247-252
Burden of illness: a systematic review of depression in chronic rhinosinusitis.
Am J Rhinol Allergy. 2016; 30: 250-256
Prevalence of nasal polyps in adults: the Skovde population-based study.
Ann Otol Rhinol Laryngol. 2003; 112: 625-629
Prevalence of nasal polyposis in France: a cross-sectional, case–control study.
Allergy. 2005; 60: 233-237
Systematic literature review of the epidemiology and clinical burden of chronic rhinosinusitis with nasal polyposis.
Curr Med Res Opin. 2020; 36: 1897-1911
Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: a meta-analysis of the literature.
J Allergy Clin Immunol. 2015; 135: 676-681.e1
Diagnosis and management of rhinosinusitis: a practice parameter update.
Ann Allergy Asthma Immunol. 2014; 113: 347-385
European position paper on rhinosinusitis and nasal polyps, 2020.
Rhinology. 2020; 58: 1-464
Endotypes of chronic rhinosinusitis with nasal polyps: pathology and possible therapeutic implications.
J Allergy Clin Immunol Pract. 2020; 8: 1514-1519
Diversity of TH cytokine profiles in patients with chronic rhinosinusitis: a multicenter study in Europe, Asia, and Oceania.
J Allergy Clin Immunol. 2016; 138: 1344-1353
The role of biologics in chronic rhinosinusitis: a systematic review.
Int Forum Allergy Rhinol. 2020; 10: 165-174
Biologics for chronic rhinosinusitis.
Cochrane Database Syst Rev. 2020; 2CD013513
Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: a systematic review for the EAACI guidelines.
Allergy. 2021; 76: 2337-2353
Indirect treatment comparison of biologics in chronic rhinosinusitis with nasal polyps.
J Allergy Clin Immunol Pract. 2021; 9: 2461-2471.e5
Aspirin desensitization vs biologics for patients with aspirin-exacerbated respiratory disease.
Ann Allergy Asthma Immunol. 2021; 126: 118-119
Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane handbook for systematic reviews of interventions, version 6.2 (updated February 2021). Cochrane, 2021. Available at: http://www.training.cochrane.org/handbook. Accessed September 20, 2021.
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations.
BMJ. 2008; 336: 924-926
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration.
J Clin Epidemiol. 2009; 62: e1-e34
The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations.
Ann Intern Med. 2015; 162: 777-784
Benefits and harms of aspirin desensitization for aspirin-exacerbated respiratory disease: a systematic review and meta-analysis.
Int Forum Allergy Rhinol. 2019; 9: 1409-1419
RoB 2: a revised tool for assessing risk of bias in randomised trials.
BMJ. 2019; 366: l4898
Drug treatments for Covid-19: living systematic review and network meta-analysis.
BMJ. 2020; 370: m2980
GRADE approach to rate the certainty from a network meta-analysis: avoiding spurious judgments of imprecision in sparse networks.
J Clin Epidemiol. 2019; 105: 60-67
GRADE approach to drawing conclusions from a network meta-analysis using a minimally contextualised framework.
BMJ. 2020; 371m3900
Pooling health-related quality of life outcomes in meta-analysis—a tutorial and review of methods for enhancing interpretability.
Res Synth Methods. 2011; 2: 188-203
Development of the Instrument to assess the Credibility of Effect Modification Analyses (ICEMAN) in randomized controlled trials and meta-analyses.
CMAJ. 2020; 192: E901-E906
Addressing continuous data for participants excluded from trial analysis: a guide for systematic reviewers.
J Clin Epidemiol. 2013; 66: 1014-1021.e1
Addressing dichotomous data for participants excluded from trial analysis: a guide for systematic reviewers.
PLoS One. 2013; 8e57132
Schünemann H, Brożek J, Guyatt G, Oxman A, editors. GRADE handbook for grading quality of evidence and strength of recommendations. Updated October 2013. The GRADE Working Group, 2013. Available at: https://gdt.gradepro.org/app/handbook/handbook.html. Accessed September 20, 2021.
GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions.
J Clin Epidemiol. 2020; 119: 126-135
Reslizumab an interleukin-5 antagonist monoclonal antibody for uncontrolled chronic rhinosinusitis with nasal polyps.
Ann Allergy Asthma Immunol. 2020; 125: S49-S50
Efficacy of subcutaneous dupilumab a human anti–interleukin-4 receptor alpha monoclonal antibody for moderate-to-severe uncontrolled asthmatics.
Ann Allergy Asthma Immunol. 2018; 121: S40-S41
Omalizumab versus intranasal steroids in the post-operative management of patients with allergic fungal rhinosinusitis.
Eur Arch Otorhinolaryngol. 2020; 277: 121-128
A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis.
Rhinology. 2010; 48: 318-324
Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma.
J Allergy Clin Immunol. 2013; 131: 110-116.e1
Omalizumab for aspirin hypersensitivity and leukotriene overproduction in aspirin-exacerbated respiratory disease. A randomized controlled trial.
Am J Respir Crit Care Med. 2020; 201: 1488-1498
Anti–immunoglobulin E therapy: is it a valid option for the management of chronic rhinosinusitis with nasal polyposis?.
Egypt J Otolaryngol. 2019; 35: 269-277
Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials.
J Allergy Clin Immunol. 2020; 146: 595-605
Improvement in rhinosinusitis health related quality of life in patients with severe eosinophilic asthma.
Eur Respir J. 2017; 50 ()
Reduced need for surgery in severe nasal polyposis with mepolizumab: randomized trial.
J Allergy Clin Immunol. 2017; 140: 1024-1031.e14
Mepolizumab, a humanized anti–IL-5 mAb, as a treatment option for severe nasal polyposis.
J Allergy Clin Immunol. 2011; 128: 989-995.e1-8
Mepolizumab, a humanised anti–IL-5 monoclonal antibody, as treatment of severe nasal polyposis.
J Allergy Clin Immunol. 2008; 121 ()
Mepolizumab for chronic rhinosinusitis with nasal polyps: comorbid asthma, NSAID exacerbated respiratory disease, eosinophil stratification.
Ann Allergy Asthma Immunol. 2020; 125: S47
Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial.
Lancet Respir Med. 2017; 5: 390-400
Mepolizumab improves health related quality of life for patients with chronic rhinosinusitis with nasal polyps: data from the SYNAPSE study.
J Allergy Clinical Immunol. 2021; 147: AB125
Nasal IL-5 levels determine the response to anti–IL-5 treatment in patients with nasal polyps.
J Allergy Clin Immunol. 2006; 118: 1133-1141
Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study.
Am J Respir Crit Care Med. 2011; 184: 1125-1132
Aspirin desensitization for patients with aspirin-exacerbated respiratory disease: a randomized double-blind placebo-controlled trial.
Clin Immunol. 2015; 160: 349-357
Low-dose aspirin desensitization in individuals with aspirin-exacerbated respiratory disease.
Allergy. 2013; 68: 659-665
Clinical and immunological efficacy of aspirin desensitization in nasal polyp patients with aspirin-exacerbated respiratory disease.
Iran J Pharm Res. 2017; 16: 1639-1647
Aspirin-sensitive rhinosinusitis asthma: a double-blind crossover study of treatment with aspirin.
J Allergy Clin Immunol. 1984; 73: 500-507
Aspirin desensitization in patients with aspirin-induced and aspirin-tolerant asthma: a double-blind study.
J Allergy Clin Immunol. 2014; 134: 883-890
Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Respir Med. 2021; 9: 1141-1153
Benralizumab effect on severe chronic rhinosinusitis with nasal polyps (CRSwNP): a randomized double-blind placebo-controlled trial.
Clin Exp Allergy. 2021; 51: 836-844
Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma.
N Engl J Med. 2018; 378: 2486-2496
Dupilumab improves SNOT-22 scores in asthma patients with chronic rhinosinusitis or nasal polypsosis (CRS/NP) in liberty asthma quest.
Eur Respir J. 2018; 52 ()
Canonica GW, Harrison TW, Chanez P, Menzella F, Louis R, Cosio BG, et al. Benralizumab improves symptoms of patients with severe, eosinophilic asthma with a diagnosis of nasal polyposis. Allergy. In press.
Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial.
Lancet Respir Med. 2021; 9: 260-274
Dupilumab improves nasal polyp burden and asthma control in patients with CRSwNP and NSAID-ERD.
Allergy Eur J Allergy Clin Immunol. 2018; 73: 203
Dupilumab improves nasal polyp burden and asthma control in patients with CRSwNP and AERD.
J Allergy Clin Immunol In Practice. 2019; 7: 2462-2465.e1
Dupilumab (DPL) efficacy in patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) with/without nonsteroidal anti-inflammatory drug–exacerbated respiratory disease (NSAID-ERD): SINUS-24, SINUS-52 trials.
Eur Respir J. 2019; 54 ()
Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial.
JAMA. 2016; 315: 469-479
Phenotypes and emerging endotypes of chronic rhinosinusitis.
J Allergy Clin Immunol Pract. 2016; 4: 621-628
IL-33, but not thymic stromal lymphopoietin or IL-25, is central to mite and peanut allergic sensitization.
J Allergy Clin Immunol. 2013; 131: 187-200.e1-8
How clinically relevant are treatment comparisons of topical calcineurin inhibitor trials for atopic eczema?.
J Invest Dermatol. 2016; 136: 1944-1949
Omalizumab can inhibit respiratory reaction during aspirin desensitization.
Ann Allergy Asthma Immunol. 2018; 121: 98-104
Biologic therapies versus surgical management for aspirin-exacerbated respiratory disease: a review of preliminary data, efficacy, and cost.
World J Otorhinolaryngol Head Neck Surg. 2020; 6: 230-234
Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.
Lancet. 2019; 394: 1638-1650
Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma.
N Engl J Med. 2018; 378: 2475-2485
A Phase II, multicenter, randomized, placebo-controlled study of benralizumab, a humanized anti-IL-5R alpha monoclonal antibody, in patients with eosinophilic chronic rhinosinusitis.
Am J Rhinol Allergy. 2021; https://doi.org/10.1177/19458924211009429
Dupilumab improves upper and lower airway disease control in chronic rhinosinusitis with nasal polyps and asthma.
Ann Allergy Asthma Immunol. 2021; 126: 584-92 e1